WHC is still in active development. Read this to understand our approach.
depiction of PJNSMUBMSNAEEN-UHFFFAOYSA-N.svg
tripsit

noopept

Verificar en tripsit

psychonaut

Omberacetam

Verificar en psychonaut

isomerdesign

Noopept

Verificar en isomerdesign

druglab

Noopept

Verificar en druglab

drugmap

SGS-111

Verificar en drugmap

wiki

N-Phenylacetyl-L-pro...

Verificar en wiki

Data

InChI: InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)

Sinónimos: N-Phenylacetyl-L-prolylglycineethyl ester,Glycine, 1-(2-phenylacetyl)-L-prolyl-, ethyl ester,GVS 111,Omberacetam [WHO-DD],SGS-111,N-Phenylacetyl-L-prolylglycine ethyl ester, DVD-111,ethyl (2-phenylacetyl)-L-prolylglycinate,NOOPEPT [WHO-DD],HY-17456,Ethyl N-[1-(Phenylacetyl)-L-prolyl]glycinate,1-(2-phenylacetyl)-l-prolylglycine ethyl ester,N-[1-(Phenylacetyl)-L-prolyl]glycine Ethyl Ester,ethyl 2-{[(2S)-1-(2-phenylacetyl)pyrrolidin-2-yl]formamido}acetate,n-phenylacetyl-l-prolylglycine ethyl ester,Omberacetam,NCGC00378939-05,N1120,DVD-111,4QBJ98683M,(S)-Ethyl 2-(1-(2-phenylacetyl)pyrrolidine-2-carboxamido)acetate,DTXSID80166214,ethyl 1-(phenylacetyl)-L-prolylglycinate,ethyl phenylacetyl-Pro-Gly,GVS-111,UNII-4QBJ98683M,CHEMBL4303687,115P850,AS-10555,Q7049784,Noopept, >=98% (HPLC),Noopept,J759.455K,N-(1-(Phenylacetyl)-L-prolyl)glycine ethyl ester, GVS-111,OMBERACETAM [INN],157115-85-0,ZINC3812682,Glycine, N-(1-(phenylacetyl)-L-prolyl)-, ethyl ester,CS-1575,AKOS016012268,ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate,C72975,SCHEMBL194807,Glycine, 1-(phenylacetyl)-L-prolyl-, ethyl ester,AM84514

Market name: noopept

Estimated data

Solubilidad: -2.68 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 46.0% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.